Monograph Details
|
|
Eye Disorders
> Glaucoma
|
|
BETAGAN |
| Manufacturer |
|
Allergan |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Noncardioselective β-blocker. |
| Generic Name |
|
Levobunolol HCl 0.25%, 0.5%; oph. soln; contains benzalkonium chloride. |
| Indications |
|
Open-angle glaucoma. |
| Children |
|
Not recommended. |
| Adults |
|
1–2 drops of 0.5% 1–2 times daily or 1–2 drops of 0.25% 2 times daily. |
| Contraindications |
|
Bronchial asthma. Severe COPD. Sinus bradycardia. 2nd- or 3rd-degree AV block. Overt cardiac failure. Cardiogenic shock. |
| Precautions |
|
Diabetes. Hyperthyroidism. Diminished pulmonary function. Angle-closure glaucoma. Myasthenia. Withdraw gradually before surgery. Discontinue at first sign of cardiac failure. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Additive effects with systemic β-blockers, reserpine. Mydriasis with epinephrine. |
| Adverse Reactions |
|
Systemic absorption (bronchospasm, cardiac failure), transient ocular burning, stinging, blepharoconjunctivitis, bradycardia, hypotension, iridocyclitis, headache, transient ataxia, dizziness, lethargy, urticaria, pruritus, decreased corneal sensitivity. |
| How Supplied |
Soln 0.25%—5mL, 10mL
0.5%—2mL, 5mL, 10mL, 15mL |
|
|
|
|
